Development and validation of the Korean version of the Female Sexual
                    Function Index-5 (FSFI-5)

Chung, Seung Jun; Yang, Dong-Ouk; Yu, Ho Song; Park, Kwangsung

doi:10.34224/kjsh.2019.3.1.3

Cited by 3 publications

(2 citation statements)

References 20 publications

(19 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, RHAMM as a regulator of CD44-ERK-1/2 fibroblast signalling, is required for mucosal regeneration and to improve urothelial lining defects in cystitis rats (Iavazzo et al, 2007;Ahmad et al, 2008;Cervigni et al, 2008;Lee et al, 2017). Our animal study revealed that after dextrose prolotherapy, the regeneration of the uroepithelium glycosaminoglycan layer and the gene expression of the HA and HAS receptors were increased in the CYP-induced rats (Figures 3,4,5). The HA was initially synthesized on the inner surface of the cell by HAS and released into the extracellular space.…”

Section: Discussionmentioning

confidence: 67%

See 1 more Smart Citation

A Novel Intravesical Dextrose Injection Improves Lower Urinary Tract Symptoms on Interstitial Cystitis/Bladder Pain Syndrome

et al. 2021

View full text Add to dashboard Cite

Interstitial cystitis/bladder pain syndrome (IC/BPS) is a painful recurrent condition characterized by the discomfort of the bladder, and current treatment options have limited effectiveness. Prolotherapy is a well-known treatment that involves the injection of non-biologic solutions to reduce pain and/or promote proliferation of soft tissue, and dextrose is the most common injectate. This study investigated the effects of dextrose prolotherapy in a rat model of IC/BPS and patients with IC/BPS. We used cyclophosphamide to induce IC/BPS in rats, and intravesical instillation of 10% dextrose solution was performed. After 1 week, we conducted a urodynamic test, bladder staining, and ECM-related gene expression analysis to examine the treatment’s efficacy. We found that dextrose treatment could recover the instability of the bladder, reduce frequent urination, and improve the glycosaminoglycan layer regeneration and the bladder wall thickness along with a significant intense expression of CD44 receptors. Furthermore, we enrolled 29 IC/BPS patients with previous hyaluronic acid/Botox treatment for more than 6 months with remained unchanged condition. In this study, they received intravesical injections of 10% dextrose solution followed by assessments for up to 12 weeks. Patient characteristics and a 3-day voiding diary before treatment were recorded. Patient responses were examined using IC/BPS-related questionnaires. Moreover, expressions of growth factors and cytokines were analyzed. The results demonstrated that dextrose prolotherapy in patients with IC/BPS reduced the frequency of treatment over time, with the mean number of treatments being 3.03 ± 1.52, and significantly reduced the incidence of nocturia and questionnaire scores associated with symptoms. Dextrose prolotherapy significantly enhanced EGF level and, in contrast, reduced the level of HGF, PIGF-1, and VEGF-D after several weeks following treatment. The cytokine analysis showed that the expressions of IL-12p70 and IL-10 were significantly up-regulated after dextrose prolotherapy in IC/BPS patients. The levels of most growth factors and cytokines in IC/BPS patients had no significant difference and showed a similar tendency as time progressed when compared to healthy controls. Overall, the alteration of growth factors and cytokines exhibited safe treatment and potential stimulation of tissue remodeling. In summary, our study demonstrated that dextrose prolotherapy is a promising treatment strategy for IC/BPS disease management.

show abstract

Section: Discussionmentioning

confidence: 67%

“…The quality of life (QoL) of patients was evaluated using BSRS-5 questionnaire ( Chen et al, 2005 ). In addition, the sexual dysfunction in female patients was assessed using FSFI-5 questionnaire ( Chung et al, 2019 ).…”

Section: Methodsmentioning

confidence: 99%